CureVac N.V. announced that Dr. Igor Splawski, CureVac's Chief Scientific Officer, will step down effective July 14, 2023 to return to early-stage research in the United States. During the search for a successor, CureVac's Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac's unique mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.49 USD | -10.02% | +15.42% | +6.65% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.65% | 1.01B | |
+51.85% | 57.87B | |
+41.25% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac N.V. Announces Executive Changes